Rayence Co

Rayence Co Equity Ratio

The Equity Ratio of Rayence Co (228850.KQ) as of Oct 22, 2026 is 90.71 %. In the previous year, Equity Ratio was 90.78 % — a change of -0.07% (lower).

Equity Ratio

90.71 %

YoY

-0.07%

Last updated:

Equity Ratio of Rayence Co is 2025 90.71 % . Equity Ratio of Rayence Co was 2024 90.78 % . It decreases by -0.07% lower compared to the previous year.

The Rayence Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
90.42 KRW
Jan 1, 2019
83.72 KRW
Jan 1, 2020
83.73 KRW
Jan 1, 2021
82.95 KRW
Jan 1, 2022
85.78 KRW
Jan 1, 2023
86.57 KRW
Jan 1, 2024
90.78 KRW
Jan 1, 2025
90.71 KRW
The Rayence Co Equity Ratio history
YEAREquity RatioYoY
90.71 %-0.07%
90.78 %+4.86%
86.57 %+0.92%
85.78 %+3.41%
82.95 %-0.93%
83.73 %+0.01%
83.72 %-7.41%
90.42 %+0.56%
89.92 %+3.47%
86.90 %+36.22%
63.79 %+10.34%
57.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Equity Ratio of Rayence Co is 90.71 % in 2025.

Equity Ratio of Rayence Co changed from 90.78 % to 90.71 %, representing a -0.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Rayence Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Rayence Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rayence Co

All Key Metrics — Rayence Co